Abstract
Even though ibritumomab tiuxetan provides clinical benefit to follicular lymphoma patients, resistance to ibritumomab tiuxetan develops. Follicular lymphoma shows a remarkable diversity in phenotypic, genetic, and microenvironment intratumoral heterogeneities.
Heterogeneity is one of the most clinically relevant and rapidly evolving fields of cancer research. Despite this growing excitement in the fundamental research, tumor heterogeneity has little practical impact on today’s management of cancer patients.
Therefore, understanding the mechanisms for resistance to ibritumomab tiuxetan and developing treatment strategies are important.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Storto G, De Renzo A, Pellegrino T, Perna F, De Falco T, Erra P, et al. Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Radiology. 2010;254(1):245–52.
Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109(9):1804–10.
Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med. 2005;46(11):1812–8.
Jacobs SA, Harrison AM, Swerdlow SH, Foon KA, Avril N, Vidnovic N, et al. Radioisotopic localization of (90)yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma. Mol Imaging Biol. 2009;11(1):39–45.
Iagaru A, Gambhir SS, Goris ML. 90Y-ibritumomab therapy in refractory non-Hodgkin’s lymphoma: observations from 111In-ibritumomab pretreatment imaging. J Nucl Med. 2008;49(11):1809–12.
Amro H, Wilderman SJ, Dewaraja YK, Roberson PL. Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy. J Nucl Med. 2010;51(4):654–9.
Hrycushko BA, Ware S, Li S, Bao A. Improved tumour response prediction with equivalent uniform dose in pre-clinical study using direct intratumoural infusion of liposome-encapsulated 186Re radionuclides. Phys Med Biol. 2011;56(17):5721–34.
O’Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med. 1999;40(8):1337–41.
Kalogianni E, Flux GD, Malaroda A. The use of BED and EUD concepts in heterogeneous radioactivity distributions on a multicellular scale for targeted radionuclide therapy. Cancer Biother Radiopharm. 2007;22(1):143–50.
Jacene HA, Filice R, Kasecamp W, Wahl RL. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med. 2009;50(1):8–17.
Lopci E, Santi I, Derenzini E, Fonti C, Savelli G, Bertagna F, et al. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. Ann Oncol. 2010;21(9):1877–83.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.
Assie K, Dieudonne A, Gardin I, Buvat I, Tilly H, Vera P. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin’s lymphoma. Cancer Biother Radiopharm. 2008;23(1):53–64.
Lopci E, Santi I, Tani M, Maffione AM, Montini G, Castellucci P, et al. FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma. Q J Nucl Med Mol Imaging. 2010;54(4):436–41.
Dieudonne A, Hobbs RF, Bolch WE, Sgouros G, Gardin I. Fine-resolution voxel S values for constructing absorbed dose distributions at variable voxel size. J Nucl Med. 2010;51(10):1600–7.
Flux G, Bardies M, Monsieurs M, Savolainen S, Strands SE, Lassmann M. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys. 2006;16(1):47–59.
Jentzen W, Weise R, Kupferschlager J, Freudenberg L, Brandau W, Bares R, et al. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging. 2008;35(3):611–23.
Fabbri C, Sarti G, Cremonesi M, Ferrari M, Di Dia A, Agostini M, et al. Quantitative analysis of 90Y bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry. Cancer Biother Radiopharm. 2009;24(1):145–54.
Hughes T, Celler A. A multivendor phantom study comparing the image quality produced from three state-of-the-art SPECT-CT systems. Nucl Med Commun. 2012;33(6):663–70.
Cazaentre T, Morschhauser F, Vermandel M, Betrouni N, Prangere T, Steinling M, et al. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(3):494–504.
Hanaoka K, Watabe T, Naka S, Kanai Y, Ikeda H, Horitsugi G, et al. FBPA PET in boron neutron capture therapy for cancer: prediction of (10)B concentration in the tumor and normal tissue in a rat xenograft model. EJNMMI Res. 2014;4(1):70.
Watabe T, Tatsumi M, Watabe H, Isohashi K, Kato H, Yanagawa M, et al. Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CT. Ann Nucl Med. 2012;26(3):222–7.
Vicini P, Bonadonna RC, Utriainen T, Nuutila P, Raitakari M, Yki-Jarvinen H, et al. Estimation of blood flow heterogeneity distribution in human skeletal muscle from positron emission tomography data. Ann Biomed Eng. 1997;25(5):906–10.
Baek HJ, Kim HS, Kim N, Choi YJ, Kim YJ. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. Radiology. 2012;264(3):834–43.
Hanaoka K, Hosono M, Tatsumi Y, Ishii K, Im SW, Tsuchiya N, et al. Heterogeneity of intratumoral (111)in-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma. EJNMMI Res. 2015;5:10.
Conflict of Interest
No conflict statement: No potential conflicts of interest were disclosed.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Hanaoka, K., Hosono, M. (2018). Resistance and Heterogeneity of Intratumoral Antibody Distribution. In: Hosono, M., Chatal, JF. (eds) Resistance to Ibritumomab in Lymphoma. Resistance to Targeted Anti-Cancer Therapeutics, vol 18. Springer, Cham. https://doi.org/10.1007/978-3-319-78238-6_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-78238-6_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-78237-9
Online ISBN: 978-3-319-78238-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)